Cancer Genetics (CGIX) Sees IPO Price in $11-$13/Share Range
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/1/2026
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Dollar pushes higher, yen sinks to 40-year low
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- DISH DBS files prepackaged chapter 11 to repay debt, wind down wireless
- Boeing commercial jet deliveries and production disrupted by widespread IT outage - Air Current
- Cantor Fitzgerald Starts Forward Industries (FWDI) at Overweight
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
Cancer Genetics (CGIX) Adjusts Expected IPO Price to $10 - $12/Share
March 4, 2013 10:35 AM ESTCancer Genetics (Nasdaq: CGIX) filed an amended registration with the U.S. SEC for an Initial Public Offering of its Common Stock. The company plans to sell 1.85 million shares and sees an offering price of $10 to $12 per share. Prior expectations from the... More
